SCHEMBL2875632

SCHEMBL2875632

O=C(O)Cc1c(-c2ccc(Cl)c(S(=O)(=O)NCc3ccc(Cl)cc3Cl)c2)[nH]c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
PKM P14618 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MCL1 Q07820 1/20 0.41
ACLY P53396 1/20 0.40
POLB P06746 1/20 0.40
CNR1 P21554 4/20 0.40
HDAC8 Q9BY41 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
NR3C1 P04150 1/20 0.39
SLC12A2 P55011 1/20 0.39
SLC12A5 Q9H2X9 1/20 0.39
GRIN1 Q05586 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2875685 0.92 MGAM (0.47) LMNAMAPTPKMCNR1HDAC8
SCHEMBL5511878 0.88 LMNA (0.53) LMNAMAPTMCL1POLBCNR1
SCHEMBL2875504 0.88 CNR1 (0.43) LMNAMAPTMCL1POLBCNR1
SCHEMBL2875982 0.87 CNR1 (0.45) LMNAMAPTMCL1CNR1PTGDR2
SCHEMBL5510544 0.83 ALDH1A1 (0.44) MAPTMCL1CNR1KDM4EALDH1A1
SCHEMBL5510986 0.83 CNR1 (0.41) LMNAMAPTKMT2ACNR1SLC12A2
SCHEMBL5521146 0.82 ALDH1A1 (0.47) MAPTMCL1KDM4EALDH1A1GAA
SCHEMBL2873034 0.82 MGAM (0.46) MAPTPOLB
SCHEMBL5508823 0.81 ALDH1A1 (0.49) LMNAMAPTMEN1KMT2APOLB
SCHEMBL5516600 0.81 CNR1 (0.52) LMNAMAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066628-B1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI AVENTIS (FR) 2010-10-20 EP disclosed
EP-2066628-B1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI AVENTIS (FR) 2010-10-20 EP disclosed
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
WO-2008014186-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS PTGER2, PTGDR2, CYSLTR2 LMNA 4387/4885MAPT 2271/4885PKM 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.